HER3 targeting with an antibody‐drug conjugate bypasses resistance to anti‐HER2 therapies

Despite impressive clinical benefit obtained with anti‐HER2‐targeted therapies, in advances stages, especially in the metastatic setting, HER2‐positive tumors remain incurable. Therefore, it is important to develop novel strategies to fight these tumors, especially when they become resistant to avai...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandullo‐Sánchez, Lucía, Capone, Emily, Ocaña, Alberto, Iacobelli, Stefano, Sala, Gianluca, Pandiella, Atanasio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207167/
https://www.ncbi.nlm.nih.gov/pubmed/32329582
http://dx.doi.org/10.15252/emmm.201911498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207167/
https://www.ncbi.nlm.nih.gov/pubmed/32329582
http://dx.doi.org/10.15252/emmm.201911498

Ejemplares similares